SLS SELLAS Life Sciences Group, Inc. - Common Stock
NASDAQ · Biotechnology · Lihat di SEC EDGAR ↗ tutup Okt 2, 2026 10-K/10-Q Agu 11, 2026SLS Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu
SLS Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
| Tanggal ex-dividen | Pemecahan | Tipe |
|---|---|---|
| 8 Nov. 2019 | 1-for-50 | Terbalik |
| 2 Jan. 2018 | 1-for-30 | Terbalik |
| 14 Nov. 2016 | 1-for-20 | Terbalik |
Tentang SELLAS Life Sciences Group, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia
Galena Biopharma, Inc. (originally RXi Pharmaceuticals) was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc. (Nasdaq: SLS).
History
In November 2006, Argonaut Pharmaceuticals, Inc. changed the name to RXi Pharmaceuticals Corporation. RXi was a subsidiary of CytRx Corp., which provided $15 million in financing in April 2007. RXi was founded in part by Nobel Prize winner Craig Mello. In September 2007, RXi signed a licensing deal with TriLink Biotechnologies, a competitor in the RNA interference (RNAi) field, in which RXi would pay TriLink to use three of TriLink's technologies.
In March 2011, the company announced the planned acquisition of Arizona-based Apthera, Inc. for $7 million. The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug Administration to start a stage three clinical trial.
In September 2011, the company separated its cancer therapies division. It was renamed Galena Biopharma Inc and moved to Lake Oswego, Oregon. RXi became a subsidiary of Galena and retained RNAi technologies. RXi Pharmaceuticals remained in Massachusetts as a publicly traded company. In January 2014, Galena bought Mills Pharmaceuticals. In April 2014, the company headquarters moved to Portland.
In November 2011, the company partnered with Genentech to combine drugs from each company for a cancer treatment. Galena is currently studying the combination of NeuVax and Herceptin in phase II trials.
Leadership
In March 2011, president and CEO Noah Beerman were replaced by Mark Ahn, and in August 2014, Ahn resigned and was replaced by Mark Schwartz. On January 31, 2017, Galena announced the resignation of Mark Schwartz effective that day, and reported in the same press release that it would be exploring strategic alternatives to maximize shareholder value going forward.
Stock
RXi went public in March 2008. CytRx retained 49% ownership of RXi's stock and gave shares of RXi to existing shareholders. Trading began on the Nasdaq market on March 12, 2008, under the ticker symbol of RXII. Fidelity Investments invested $8.5 million in the company in May 2008, followed by a $25 million private-equity investment by Yorkville in February 2009. In 2010, RXi received a National Institutes of Health grant of $600,000. By August 2010, the company had 30 employees. In April 2011, RXi raised about $12 million from a stock offering and received $580,000 in grants from the National Institutes of Health. The company reported a loss of $11.5 million loss for 2011.
In November 2012, an anonymous internet report caused Galena stock to decline. The company filed a lawsuit claiming the report was false and attempted to manipulate the stock. In 2014, Galena's involvement in a fraudulent stock promotion scheme was exposed. On February 1, 2014, analyst Matt Gravitt published an article that revealed Galena had paid MissionIR, DreamTeam brand, to promote Galena's stock. Galena's stock fell 20% following this revelation that received a heated response, and was one of the three most read articles in Seeking Alpha's history. Over the next few weeks, more revelations came out and the company admitted their stock promotion relationship and insider selling. Galena then disclosed that the SEC was investigating their relationship with The DreamTeam Group. By March 2014, five lawsuits were filed against Galena and several of its officers alleging that the company used misleading articles to boost stock prices. Motley Fool, discussing the 23% stock price drop during March 2015, noted there was stock dilution from the offering and also that Abstral's sales were below Galena's estimates from late 2013. Discussing the Motley Fool article, Portland Business Journal also noted the ongoing insider-trading lawsuits as a factor in the stock price. A few days later, Zacks Investment Research said Galena could be a "great candidate" to beat its earnings. In response, Galena's CEO said there were many positive aspects to the company, and that the lawsuits weren't a worry as they should get covered under Directors and officers liability insurance. The company moved to San Ramon, California, in the Bay Area in 2015.
Stock promotion scandal
The revelation that Galena was engaging in fraudulent stock promotion without adequate disclosure led to the investigation of other biotech companies who engaged in similar activities. Richard Pearson, an investor who went undercover to investigate the stock promotion firms, wrote an exposé on DreamTeam and its ties to articles about Galena, CytRx, and other companies on media websites. In April 2017, the Securities and Exchange Commission announced enforcement actions against 27 individuals and entities behind various alleged stock promotion schemes. Fraud charges were filed against three public companies, seven stock promotion or communications firms, and two company CEOs; also on this hit list are six individuals and nine writers.
Merger with Sellas Life Sciences
In 2017, Galena Biopharma Inc. announced a merger "with privately-held oncology company Sellas Life Sciences Group Ltd. in an all-stock transaction." The combined company was Sellas Life Science Group. The newly merged companies focused on the development of novel treatments for cancer.
Products
Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug with Genentech's Herceptin.
In 2013, Galena began selling its first developed drug, an analgesic for cancer pain named Abstral Sublingual.
Anagrelide controlled-released (GALE-401) was approved by the FDA for phase III clinical trials for the treatment of essential thrombocytosis in December 2016.
GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers.
== References ==
Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗
Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS
Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?
| Metrik | Tren 5 Tahun | SLS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| P/E | -55.6rata-rata 5T ≈-4.6 | ≈-4.6 | · | · | |
| P/B (MRQ) | 17.2rata-rata 5T ≈5.3 | ≈5.3 | 4.4 | Terlalu mahal | |
| Price / Cash Flow (Harga / Arus Kas) | -75.0rata-rata 5T ≈-5.8 | ≈-5.8 | · | · | |
| Price / Tangible Book (Harga / Nilai Buku Berwujud) | 30.9rata-rata 5T ≈10.1 | ≈10.1 | · | · |
Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.
Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC
| Metrik | Tren 5 Tahun | SLS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| ROA | -54.9%rata-rata 5T ≈-160.6% | ≈-160.6% | -40.3% | Lemah | |
| ROE | -55.4%rata-rata 5T ≈-45.6% | ≈-45.6% | -50.3% | Lemah | |
| ROIC | -39.9%rata-rata 5T ≈-177.1% | ≈-177.1% | -39.9% | Sejajar |
Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca
| Metrik | Tren 5 Tahun | SLS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Rasio Lancar (MRQ) | 18.8rata-rata 5T ≈3.7 | ≈3.7 | 14.8 | Likuiditas kuat | |
| Quick Ratio (Rasio Cepat) | 10.2rata-rata 5T ≈3.5 | ≈3.5 | 8.7 | Likuiditas kuat |
Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T
Data fundamental belum cukup untuk menghitung grup rasio ini.
Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang
| Metrik | Tren 5 Tahun | SLS | rata-rata 5T | Median Rekan | Kesimpulan |
|---|---|---|---|---|---|
| Revenue / Employee (Pendapatan Tahunan ÷ karyawan (jumlah karyawan, yfinance). Turunan — bukan konsep SEC-XBRL yang tersimpan.) | ≈$0.00 | · | · | · |
nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median
Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
| Periode | Laporan | EPS Aktual | EPS Estimasi | Kejutan |
|---|---|---|---|---|
| 30 Juni 2026 | Agu 10, 2026 | $-0.05 | $-0.05 | -9.9% |
| 31 Maret 2026 | Mei 11, 2026 | $-0.05 | $-0.04 | -23.8% |
| 31 Des. 2025 | $-0.05 | $-0.07 | 23.9% | |
| 30 Sep. 2025 | $-0.06 | $-0.07 | 10.0% | |
| 30 Juni 2025 | $-0.07 | $-0.08 | 15.9% | |
| 31 Maret 2025 | $-0.07 | $-0.11 | 34.0% | |
| 31 Des. 2024 | $-0.08 | $-0.11 | 26.2% |
Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | $0 | $1M | $8M | $2M | $0 | · | · | · | · | $9M | |
| Cost of Revenue | $0 | $0 | $0 | $100.0K | $200.0K | $0 | · | · | · | · | · | $1M | |
| R&D Expense | · | · | · | · | $16M | $9M | $7M | $9M | $6M | $11M | · | · | |
| SG&A Expense | $12M | $12M | $14M | $13M | $11M | $10M | $10M | $13M | $15M | $5M | · | · | |
| Operating Expenses | $28M | $32M | $38M | $43M | $33M | $19M | $20M | $31M | $23M | $32M | $34M | $44M | |
| Operating Income | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | $-20M | · | $-23M | $-16M | $-34M | $-44M | |
| Other Non-op | $1M | $632.0K | $529.0K | $649.0K | $4M | $208.0K | $-19M | $-29M | $-24M | $5M | $509.0K | $170.0K | |
| Pretax Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-29M | $-24M | $-18M | $-39M | $-28M | |
| Income Tax | $0 | $0 | $0 | $0 | $-237.0K | $-17.0K | $-81.0K | $-1M | $300.0K | $1.0K | $365.0K | $0 | |
| Net Income | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| EPS (Basic) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| EPS (Diluted) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · | |
| Shares (Basic) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| Shares (Diluted) | 109,051,215 | 61,202,412 | 27,777,111 | 19,395,709 | 15,481,113 | 7,977,104 | · | · | · | · | · | · | |
| EBITDA | $-28M | $-32M | $-38M | $-42M | $-25M | $-17M | · | · | $-23M | $-32M | · | · |
Neraca
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $72M | $14M | $3M | $17M | $21M | $35M | $7M | $5M | $2M | $6M | $1M | $24M | |
| Receivables | · | · | · | · | $0 | · | · | · | · | · | · | $2M | |
| Inventory | · | · | · | · | · | · | · | · | · | · | $0 | $655.0K | |
| Prepaid Expense | $3M | $2M | $542.0K | $531.0K | $2M | $395.0K | $557.0K | $387.0K | $337.0K | $332.0K | $1M | $1M | |
| Current Assets | $75M | $16M | $3M | $18M | $23M | $37M | $8M | $6M | $13M | $6M | $54M | $52M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | $199.0K | $335.0K | $285.0K | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $6M | $6M | |
| Total Assets | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Accounts Payable | $3M | $4M | $6M | $3M | $2M | $5M | $4M | $4M | $12M | $840.0K | $2M | $2M | |
| Accrued Liabilities | $4M | $5M | $8M | $6M | $3M | $2M | $1M | $2M | $3M | $4M | $5M | $9M | |
| Current Liabilities | $7M | $10M | $14M | $16M | $5M | $12M | $5M | $6M | $25M | $6M | $57M | $27M | |
| Capital Leases | $457.0K | $457.0K | $460.0K | $573.0K | $610.0K | $825.0K | $0 | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | $0 | $239.0K | $262.0K | $357.0K | $2M | · | · | · | |
| Total Liabilities | $7M | $10M | $14M | $16M | $6M | $18M | $11M | $12M | $31M | $11M | $69M | $43M | |
| Long-term Debt | · | · | · | · | · | · | · | $0 | $11M | · | $5M | $8M | |
| Total Debt | · | · | · | · | · | · | · | · | $11M | $16M | · | · | |
| Common Stock | $15.0K | $7.0K | $3.0K | $2.0K | $2.0K | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $15.0K | $12.0K | |
| Retained Earnings | $-275M | $-248M | $-217M | $-180M | $-139M | $-118M | $-101M | $-82M | $-54M | $-30M | · | · | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | $4M | $4M | $4M | |
| Stockholders' Equity | $71M | $9M | $-8M | $5M | $20M | $28M | $6M | $5M | $2M | $-5M | $-12M | $37M | |
| Liabilities + Equity | $78M | $19M | $6M | $21M | $26M | $46M | $17M | $17M | $34M | $6M | $82M | $80M | |
| Shares Outstanding | 153,103,459 | 73,977,459 | 32,132,890 | 21,005,405 | 15,895,637 | 14,254,554 | 5,080,100 | 440,529 | 5,766,891 | 1,268,489 | 8,095,337 | 109,425,701 |
Arus Kas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $3.0K | $107.0K | $86.0K | |
| Stock-based Comp | $2M | $2M | $2M | $2M | $1M | $578.0K | $573.0K | $395.0K | $3M | $354.0K | $2M | $5M | |
| Deferred Tax | · | · | · | $0 | $-239.0K | $-22.0K | $-95.0K | $-1M | $39.0K | $-41.0K | $365.0K | $0 | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $0 | $2M | · | · | $440.0K | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $-24M | · | · | |
| Operating Cash Flow | $-28M | $-35M | $-31M | $-24M | $-26M | $-10M | $-18M | $-30M | $-11M | $-12M | $-48M | $-43M | |
| CapEx | · | · | · | · | · | · | · | · | · | $6.0K | $153.0K | $57.0K | |
| Investing Cash Flow | · | $0 | $-6M | $-4M | $0 | · | · | $0 | $12M | $-85.0K | $10M | $-6M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $2M | $0 | $0 | |
| Net Debt Issued | · | · | · | · | · | · | $0 | · | · | $18M | · | · | |
| Stock Issued | · | $0 | $289.0K | $1M | $9M | $30M | $16M | $22M | $6M | $34M | $47M | $11M | |
| Net Stock Activity | · | $0 | $289.0K | $1M | $9M | $30M | $16M | · | $6M | $34M | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · | |
| Financing Cash Flow | $86M | $47M | $22M | $24M | $12M | $38M | $20M | $23M | $6M | $16M | $44M | $24M | |
| Net Change in Cash | $58M | $11M | $-15M | $-4M | $-14M | $28M | $2M | $-7M | $7M | $5M | $6M | $-24M | |
| Taxes Paid | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-45M | · | · |
Profitabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| Net Margin | · | · | · | -4130.1% | -272.4% | -881.9% | -16349.1% | · | 5141.6% | · | · | · | |
| Pretax Margin | · | · | · | -4130.1% | -275.5% | -882.8% | -16417.0% | · | 5086.8% | · | · | · | |
| EBITDA Margin | · | · | · | -4195.0% | -332.8% | -893.8% | · | · | 4986.8% | · | · | · | |
| ROA | -54.9% | -240.8% | -274.9% | -174.9% | -57.2% | -53.5% | -115.1% | · | -118.9% | -31.8% | · | · | |
| ROE | -55.4% | -243.6% | 632.7% | -473.4% | -88.2% | -93.3% | -340.3% | · | 1623.1% | -287.3% | · | · | |
| ROIC | -39.9% | -332.9% | 474.8% | -864.8% | -122.9% | -60.7% | · | · | -178.3% | -72.3% | · | · |
Likuiditas & Solvabilitas
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 | 3.0 | 1.6 | · | 0.5 | 1.2 | · | · | |
| Quick Ratio | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 | 2.9 | 1.4 | · | 0.1 | 0.6 | · | · | |
| Debt / Equity | · | · | · | · | · | · | · | · | 5.3 | 0.6 | · | · | |
| LT Debt / Equity | · | · | · | · | · | · | · | · | 1.3 | · | · | · |
Efisiensi
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | · | -0.0 | · | · | · |
Per Saham
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.46 | $0.13 | $-0.25 | $0.23 | $1.28 | $1.96 | $1.20 | · | $0.36 | $1.89 | · | · | |
| Revenue / Share | · | · | $0.00 | $0.05 | $0.49 | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.26 | $-0.58 | $-1.13 | $-1.23 | $-1.68 | · | · | · | · | · | · | · | |
| Cash / Share | $0.47 | $0.19 | $0.08 | $0.82 | $1.34 | $2.48 | $1.43 | · | $0.40 | $1.19 | · | · | |
| EPS (TTM) | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | · | · | · | · | · | · |
Tingkat Pertumbuhan
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -86.8% | 300.0% | · | · | · | · | · | · | · |
Valuasi (TTM)
| Metrik | Tren | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | $0 | $1M | $8M | $2M | $0 | $10M | $10M | $10M | $10M | $9M | |
| Net Income TTM | $-27M | $-31M | $-37M | $-41M | $-21M | $-17M | $-19M | $-28M | $-24M | $-18M | $-64M | $-37M | |
| Market Cap | $577M | $77M | $34M | $50M | $88M | $83M | $22M | · | $2.25B | $44.20B | · | · | |
| Enterprise Value | · | · | · | · | · | · | · | · | $2.26B | $44.20B | · | · | |
| P/E | -15.1 | -2.1 | -0.8 | -1.1 | -4.1 | -2.8 | · | · | · | · | · | · | |
| P/S | · | · | · | 49.6 | 11.6 | 43.6 | · | · | 223.1 | 4384.0 | · | · | |
| P/B | 8.1 | 8.1 | -4.3 | 10.2 | 4.3 | 3.0 | 3.6 | · | 1086.5 | 1542.5 | · | · | |
| P / Tangible Book | 8.4 | 10.2 | · | 16.9 | 4.8 | 3.2 | · | · | · | · | · | · | |
| P / Cash Flow | -20.3 | -2.2 | -1.1 | -2.1 | -3.4 | -8.0 | -1.2 | · | -204.7 | -984.2 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / EBITDA | · | · | · | · | · | · | · | · | -98.0 | -1393.3 | · | · | |
| EV / FCF | · | · | · | · | · | · | · | · | · | -984.0 | · | · | |
| EV / Revenue | · | · | · | · | · | · | · | · | 223.9 | 4383.9 | · | · | |
| Dividend Yield | · | · | · | · | · | · | 0.00% | · | 0.00% | · | · | · | |
| Earnings Yield | -6.6% | -48.1% | -126.4% | -90.2% | -24.2% | -36.3% | · | · | · | · | · | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | · | · | · | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $487.0K | $0 | · | · | · |
Laporan Laba Rugi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| SG&A Expense | $4M | $4M | $4M | $3M | $3M | $3M | $2M | $3M | $2M | $5M | $3M | $4M | $3M | $4M | $4M | $3M | |
| Operating Expenses | $11M | $9M | $8M | $7M | $7M | $6M | $7M | $7M | $8M | $10M | $8M | $9M | $9M | $11M | $9M | $7M | |
| Operating Income | $-11M | $-9M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-8M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| Other Non-op | $1M | $845.0K | $597.0K | $292.0K | $272.0K | $250.0K | $181.0K | $221.0K | $151.0K | $79.0K | $41.0K | $94.0K | $210.0K | $184.0K | $325.0K | $124.0K | |
| Net Income | $-10M | $-8M | $-8M | $-7M | $-7M | $-6M | $-7M | $-7M | $-7M | $-10M | $-8M | $-9M | $-9M | $-11M | $-9M | $-7M | |
| EPS (Basic) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| EPS (Diluted) | $-0.05 | $-0.05 | $-0.05 | $-0.06 | $-0.07 | $-0.07 | $-0.06 | $-0.10 | $-0.13 | $-0.21 | $-0.23 | $-0.33 | $-0.31 | $-0.47 | $-0.33 | $-0.34 | |
| Shares (Basic) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| Shares (Diluted) | 189,183,620 | 172,481,541 | · | 108,396,260 | 98,558,567 | 87,760,320 | · | 68,254,021 | 57,630,506 | 44,812,996 | · | 28,355,427 | 28,347,920 | 23,547,562 | · | 20,562,351 | |
| EBITDA | $-11M | $-9M | · | $-7M | $-7M | $-6M | · | $-7M | $-8M | $-10M | · | $-9M | $-9M | $-11M | · | $-7M |
Neraca
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $138M | $107M | $72M | $44M | $25M | $28M | $14M | $21M | $9M | $18M | $3M | $4M | $14M | $24M | $17M | $21M | |
| Prepaid Expense | $4M | $4M | $3M | $5M | $4M | $3M | $2M | $3M | $3M | $3M | $542.0K | $1M | $2M | $2M | $531.0K | $1M | |
| Current Assets | $143M | $111M | $75M | $49M | $29M | $32M | $16M | $24M | $12M | $22M | $3M | $5M | $16M | $26M | $18M | $23M | |
| Goodwill | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Total Assets | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Accounts Payable | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $5M | $6M | $7M | $6M | $4M | $4M | $3M | $3M | $2M | |
| Accrued Liabilities | $4M | $2M | $4M | $3M | $2M | $3M | $5M | $5M | $5M | $7M | $8M | $7M | $6M | $6M | $6M | $5M | |
| Current Liabilities | $8M | $6M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $14M | $14M | $12M | $13M | $16M | $16M | $13M | |
| Capital Leases | $157.0K | $309.0K | $457.0K | $0 | $157.0K | $309.0K | $457.0K | $0 | $161.0K | $313.0K | $460.0K | $178.0K | $302.0K | $422.0K | $573.0K | $680.0K | |
| Total Liabilities | $8M | $7M | $7M | $6M | $6M | $7M | $10M | $11M | $12M | $15M | $14M | $12M | $14M | $16M | $16M | $13M | |
| Common Stock | $20.0K | $18.0K | $15.0K | $12.0K | $10.0K | $9.0K | $7.0K | $6.0K | $5.0K | $5.0K | $3.0K | $3.0K | $3.0K | $3.0K | $2.0K | $2.0K | |
| Retained Earnings | $-293M | $-283M | $-275M | $-267M | $-261M | $-254M | $-248M | $-241M | $-234M | $-227M | $-217M | $-209M | $-200M | $-191M | $-180M | $-171M | |
| Stockholders' Equity | $138M | $107M | $71M | $46M | $26M | $28M | $9M | $16M | $3M | $10M | $-8M | $-4M | $5M | $13M | $5M | $13M | |
| Liabilities + Equity | $145M | $114M | $78M | $52M | $32M | $35M | $19M | $27M | $15M | $24M | $6M | $8M | $19M | $29M | $21M | $26M | |
| Shares Outstanding | 201,918,874 | 181,332,574 | 153,103,459 | 125,078,525 | 100,367,113 | 90,896,125 | 73,977,459 | 64,381,979 | 57,754,928 | 56,267,670 | 32,132,890 | 28,393,958 | 28,347,920 | 28,347,920 | 21,005,405 | 20,588,247 |
Arus Kas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $798.0K | $447.0K | $503.0K | $501.0K | $505.0K | $373.0K | $381.0K | $334.0K | $476.0K | $497.0K | $543.0K | $514.0K | $540.0K | $446.0K | $455.0K | |
| Operating Cash Flow | $-8M | $-9M | $-5M | $-7M | $-7M | $-9M | $-7M | $-8M | $-10M | $-11M | $-5M | $-7M | $-8M | $-12M | $-5M | $-6M | |
| Investing Cash Flow | · | · | · | · | · | · | · | $0 | · | · | $0 | $-3M | · | · | $0 | $0 | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $0 | $21.0K | $0 | $0 | $268.0K | $929.0K | $69.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $268.0K | · | · | |
| Financing Cash Flow | $39M | $44M | $32M | $26M | $4M | $24M | $8.0K | $20M | $414.0K | $27M | $3M | $54.0K | $-29.0K | $19M | $929.0K | $107.0K | |
| Net Change in Cash | $31M | $35M | $27M | $19M | $-3M | $15M | $-7M | $12M | $-9M | $16M | $-1M | $-10M | $-10M | $7M | $-4M | $-6M |
Profitabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| Net Margin | · | · | · | · | · | · | · | · | · | -12108.9% | · | · | · | · | · | · | |
| EBITDA Margin | · | · | · | · | · | · | · | · | · | -12208.9% | · | · | · | · | · | · | |
| ROA | -10.8% | -11.3% | · | -17.4% | -27.8% | -19.6% | · | -41.1% | -44.4% | -35.7% | · | -54.4% | -34.8% | -43.9% | · | -22.0% | |
| ROE | -11.7% | -12.4% | · | -22.1% | -45.4% | -31.1% | · | -117.8% | -192.6% | -83.7% | · | -211.3% | -74.0% | -129.1% | · | -35.8% |
Likuiditas & Solvabilitas
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 18.8 | 17.2 | · | 8.3 | 4.9 | 4.6 | · | 2.3 | 1.0 | 1.5 | · | 0.4 | 1.2 | 1.7 | · | 1.8 | |
| Quick Ratio | 18.3 | 16.6 | · | 7.5 | 4.2 | 4.1 | · | 2.0 | 0.8 | 1.3 | · | 0.3 | 1.0 | 1.5 | · | 1.7 |
Efisiensi
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | · | · | · | · | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Per Saham
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $0.68 | $0.59 | · | $0.36 | $0.26 | $0.31 | · | $0.25 | $0.05 | $0.17 | · | $-0.13 | $0.17 | $0.46 | · | $0.61 | |
| Revenue / Share | · | · | · | · | · | · | · | · | · | $0.00 | · | $0.00 | $0.00 | $0.00 | · | $0.00 | |
| Cash Flow / Share | · | $-0.05 | · | · | · | $-0.10 | · | · | · | $-0.24 | · | · | · | $-0.52 | · | · | |
| Cash / Share | $0.69 | $0.59 | · | $0.35 | $0.25 | $0.31 | · | $0.33 | $0.16 | $0.33 | · | $0.14 | $0.49 | $0.84 | · | $1.04 | |
| EPS (TTM) | $-0.21 | $-0.23 | · | $-0.26 | $-0.30 | $-0.36 | · | $-0.67 | $-0.90 | $-1.08 | · | $-1.44 | $-1.45 | $-1.55 | · | $-2.23 |
Valuasi (TTM)
| Metrik | Tren | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $1M | |
| Net Income TTM | $-32M | $-29M | · | $-26M | $-26M | $-27M | · | $-32M | $-34M | $-36M | · | $-38M | $-36M | $-36M | · | $-39M | |
| Market Cap | $2.98B | $767M | · | $201M | $220M | $98M | · | $80M | $69M | $57M | · | $47M | $45M | $41M | · | $42M | |
| P/E | -70.3 | -18.4 | · | -6.2 | -7.3 | -3.0 | · | -1.9 | -1.3 | -0.9 | · | -1.1 | -1.1 | -0.9 | · | -0.9 | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | 41.6 | |
| P/B | 21.7 | 7.1 | · | 4.4 | 8.4 | 3.5 | · | 5.1 | 23.6 | 5.9 | · | -12.2 | 9.2 | 3.1 | · | 3.3 | |
| P / Tangible Book | 22.0 | 7.3 | · | 4.6 | 9.1 | 3.8 | · | 5.8 | 68.8 | 7.3 | · | · | 15.2 | 3.6 | · | 3.9 | |
| P / Cash Flow | · | -86.7 | · | · | · | -10.8 | · | · | · | -5.3 | · | · | · | -3.3 | · | · | |
| Earnings Yield | -1.4% | -5.4% | · | -16.2% | -13.7% | -33.3% | · | -53.6% | -75.6% | -106.9% | · | -87.8% | -92.4% | -108.4% | · | -110.4% |
Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·
Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Pendapatan | · | · | $0 | $1M | $8M |
| Margin Operasi % | · | · | · | -4195.0% | -332.8% |
| Laba Bersih | $-27M | $-31M | $-37M | $-41M | $-21M |
| EPS Dilusian | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rasio Lancar | 10.7 | 1.7 | 0.2 | 1.1 | 4.6 |
| Rasio Cepat | 10.2 | 1.5 | 0.2 | 1.1 | 4.3 |
Data fundamental belum cukup untuk membuat laporan ini.
Pemilik institusional (13F) 234 pengaju · $1.5B total · Per tanggal 30 Sep. 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Posisi baru | Posisi yang keluar | Meningkat | Menurun | Perubahan bersih saham |
|---|---|---|---|---|
| 85 (+18 vs Kuartal sebelumnya) | 19 (+4 vs Kuartal sebelumnya) | 84 (+25 vs Kuartal sebelumnya) | 31 (+8 vs Kuartal sebelumnya) | +33.3M |
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
| Institusi | Nilai | Saham | % dari 13F yang dilacak | Tipe |
|---|---|---|---|---|
| BlackRock, Inc. | $222.437.657 | 15.070.302 | 14,45% | Saham |
| STATE STREET CORP | $191.829.196 | 12.996.558 | 12,47% | Saham |
| VANGUARD CAPITAL MANAGEMENT LLC | $121.417.310 | 8.226.105 | 7,89% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $105.640.272 | 7.157.200 | 6,86% | Opsi beli |
| GEODE CAPITAL MANAGEMENT, LLC | $72.107.010 | 4.884.175 | 4,69% | Saham |
| Anson Funds Management LP | $66.420.000 | 4.500.000 | 4,32% | Saham |
| CITADEL ADVISORS LLC | $64.157.292 | 4.346.700 | 4,17% | Opsi beli |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $61.832.592 | 4.189.200 | 4,02% | Opsi jual |
| CITADEL ADVISORS LLC | $33.333.984 | 2.258.400 | 2,17% | Opsi jual |
| VANGUARD GROUP INC | $31.922.098 | 8.467.400 | 2,07% | Saham |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $31.897.821 | 2.161.099 | 2,07% | Saham |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $30.266.812 | 2.050.597 | 1,97% | Saham |
| JONES FINANCIAL COMPANIES LLLP | $28.553.511 | 2.304.561 | 1,86% | Saham |
| Anson Funds Management LP | $27.245.484 | 1.845.900 | 1,77% | Opsi jual |
| NORTHERN TRUST CORP | $23.910.138 | 1.619.928 | 1,55% | Saham |
| PERCEPTIVE ADVISORS LLC | $22.140.000 | 1.500.000 | 1,44% | Opsi jual |
| VANGUARD FIDUCIARY TRUST CO | $19.707.050 | 1.335.166 | 1,28% | Saham |
| UBS Group AG | $18.490.693 | 1.252.757 | 1,20% | Saham |
| MORGAN STANLEY | $18.247.211 | 1.236.261 | 1,19% | Saham |
| Sio Capital Management, LLC | $18.165.132 | 1.230.700 | 1,18% | Opsi jual |
| BNP PARIBAS FINANCIAL MARKETS | $15.823.045 | 1.072.022 | 1,03% | Saham |
| BNP PARIBAS FINANCIAL MARKETS | $15.424.200 | 10.450 | 1,00% | Opsi jual |
| MILLENNIUM MANAGEMENT LLC | $13.372.560 | 906.000 | 0,87% | Opsi jual |
| BARCLAYS PLC | $11.831.616 | 801.600 | 0,77% | Opsi jual |
| Anson Funds Management LP | $11.808.000 | 800.000 | 0,77% | Opsi beli |
| BANK OF AMERICA CORP /DE/ | $11.630.128 | 787.949 | 0,76% | Saham |
| JANE STREET GROUP, LLC | $11.058.192 | 749.200 | 0,72% | Opsi beli |
| WELLINGTON MANAGEMENT GROUP LLP | $8.816.282 | 597.309 | 0,57% | Saham |
| GOLDMAN SACHS GROUP INC | $8.635.117 | 585.035 | 0,56% | Saham |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $8.339.518 | 565.008 | 0,54% | Saham |
| Bank of New York Mellon Corp | $7.823.173 | 530.025 | 0,51% | Saham |
| JANE STREET GROUP, LLC | $7.504.412 | 508.429 | 0,49% | Saham |
| Balyasny Asset Management L.P. | $7.380.000 | 500.000 | 0,48% | Opsi jual |
| LMR Partners LLP | $6.642.000 | 450.000 | 0,43% | Opsi jual |
| NOMURA HOLDINGS INC | $6.273.000 | 425.000 | 0,41% | Opsi beli |
| Nuveen, LLC | $6.180.440 | 418.729 | 0,40% | Saham |
| DIADEMA PARTNERS LP | $5.904.000 | 400.000 | 0,38% | Opsi beli |
| Invesco Ltd. | $5.540.049 | 375.342 | 0,36% | Saham |
| Swiss National Bank | $5.319.504 | 360.400 | 0,35% | Saham |
| XTX Topco Ltd | $5.300.168 | 359.090 | 0,34% | Saham |
| Ikarian Capital, LLC | $5.235.372 | 354.700 | 0,34% | Opsi jual |
| WELLS FARGO & COMPANY/MN | $4.853.368 | 328.819 | 0,32% | Saham |
| CITIGROUP INC | $4.820.483 | 326.591 | 0,31% | Saham |
| RENAISSANCE TECHNOLOGIES LLC | $4.580.973 | 310.364 | 0,30% | Saham |
| DAGCO, INC. | $4.351.740 | 1.028.780 | 0,28% | Saham |
| Everhart Financial Group, Inc. | $4.251.146 | 288.018 | 0,28% | Saham |
| Rafferty Asset Management, LLC | $3.540.806 | 239.892 | 0,23% | Saham |
| RHUMBLINE ADVISERS | $3.400.726 | 230.402 | 0,22% | Saham |
| Walleye Capital LLC | $3.377.088 | 228.800 | 0,22% | Opsi jual |
| TUDOR INVESTMENT CORP ET AL | $3.087.792 | 209.200 | 0,20% | Opsi jual |
Aktivis & pemilik 5%+ 2 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
| Pengaju | Diajukan | Kepemilikan | Status | Tujuan | Pengajuan |
|---|---|---|---|---|---|
| Equilibria Capital Management Limited (2), EQC Private Markets SAC Fund II Ltd — EQC Biotech Sely S Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely I Fund (2), EQC Private Markets SAC Fund Ltd — EQC Biotech Sely II Fund (2), EQC Private Markets II SAC Fund Ltd — EQC Biotech Sely III Fund (2), Varibobi Financial Holdings Ltd. (2), Daniel Tafur (2), Fabio López (2) ×4 pengajuan | 10 Okt. 2018 | · | Pengajuan awal | · | SEC |
| Angelos M. Stergiou, M.D., Sc.D. h.c. | 8 Jan. 2018 | · | Pengajuan awal | M&A / penjualan | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Orang dalam perusahaan 43 orang dalam · 17 pejabat · 9 direktur
| Orang Dalam | Peran | Aktivitas terakhir | Saham dimiliki | Beli 12m | Jual 12m | Bersih 12m |
|---|---|---|---|---|---|---|
| Andelos M. Stergiou | President and CEO | 16 Juni 2026 A | 1.759.183 | 0 | 0 | $0 |
| Mark W. Schwartz | President & CEO | 1 Juli 2016 J | 439.978 | 0 | 0 | $0 |
| Noah D Beerman | CEO and President | 15 Maret 2011 A | 92.994 | 0 | 0 | $0 |
| John Thomas Burns | CFO | 7 Jan. 2026 A | 554.327 | 0 | 0 | $0 |
| Gene Mack | CFO and Treasurer | 20 April 2018 A | · | 0 | 0 | $0 |
| Robert Eugene Kennedy | Vice President and CFO | 13 April 2011 A | 379.294 | 0 | 0 | $0 |
| Stephen J. Dipalma | CFO, EVP, Secretary | 15 Jan. 2009 A | · | 0 | 0 | $0 |
| Dragan Cicic | SVP, Chief Development Officer | 7 Jan. 2026 A | 557.805 | 0 | 0 | $0 |
| Robert Francomano | Chief Commercial Officer | 22 Jan. 2024 A | 40.918 | 0 | 0 | $0 |
| Barbara A Wood | EVP, Gen. Counsel, Corp. Sec. | 22 Jan. 2024 A | 117.225 | 0 | 0 | $0 |
| Nicholas J. Sarlis | Chief Medical Officer and SVP | 14 Maret 2019 A | · | 0 | 0 | $0 |
| Gregory M Torre | CRO and SVP | 13 Maret 2018 A | · | 0 | 0 | $0 |
| Kwang Lee | Principal Accounting Officer | 7 Des. 2011 P | 5.000 | 0 | 0 | $0 |
| Amy B Tata | Principlw Acctg Officer & Cont | 15 Maret 2011 A | 14.065 | 0 | 0 | $0 |
| Ramani Varanasi | VP Business Development | 15 Maret 2011 A | 41.083 | 0 | 0 | $0 |
| Konstantinos Andrikopoulos | VP, Legal | 15 April 2010 A | 5.750 | 0 | 0 | $0 |
| Dmitry Samarsky | VP, Technology Development | 31 Maret 2010 S | 0 | 0 | 0 | $0 |
| Katherine Bach Kalin | Direktur | 7 Jan. 2026 A | 154.400 | 1 | 0 | $100.806 |
| John Varian | Direktur | 7 Jan. 2026 A | 72.900 | 0 | 0 | $0 |
| Jane Wasman | Direktur | 7 Jan. 2026 A | 92.900 | 0 | 0 | $0 |
| David A Scheinberg | Direktur | 7 Jan. 2026 A | 73.082 | 0 | 0 | $0 |
| Robert L Van Nostrand | Direktur | 7 Jan. 2026 A | 82.900 | 0 | 0 | $0 |
| Stephen F Ghiglieri | Direktur | 14 Maret 2019 A | · | 0 | 0 | $0 |
| Fabio Lopez | Direktur | 12 Juni 2018 A | · | 0 | 0 | $0 |
| Irving M. Einhorn | · | 10 Okt. 2017 A | 34.690 | 0 | 0 | $0 |
| William Ashton | · | 10 Okt. 2017 A | 38.154 | 0 | 0 | $0 |
| Richard Chin | · | 10 Okt. 2017 A | 31.339 | 0 | 0 | $0 |
| Rudolph Nisi | · | 10 Okt. 2017 A | 42.918 | 0 | 0 | $0 |
| Sanford Hillsberg | · | 10 Okt. 2017 A | 56.950 | 0 | 0 | $0 |
| Mary Ann Gray | · | 10 Okt. 2017 A | 39.167 | 0 | 0 | $0 |
| Stephen S Galliker | · | 10 Okt. 2017 A | 36.039 | 0 | 0 | $0 |
| Thomas J Knapp | · | 6 Feb. 2017 A | · | 0 | 0 | $0 |
| Bijan Nejadnik | · | 17 Jan. 2017 A | 8.503 | 0 | 0 | $0 |
| Ryan Dunlap | · | 1 Juni 2016 M | 18.702 | 0 | 0 | $0 |
| Steven A Kriegsman | · | 19 Juni 2015 A | 5.000 | 0 | 0 | $0 |
| Margaret Kivinski | · | 16 Jan. 2015 A | · | 0 | 0 | $0 |
| Brian L Hamilton | · | 30 Juni 2014 J | 2.461 | 0 | 0 | $0 |
| Mark J Ahn | · | 30 Juni 2014 A | 116.225 | 0 | 0 | $0 |
| Rosemary Mazanet | · | 29 Jan. 2013 A | · | 0 | 0 | $0 |
| Anastasia Khvorova | · | 24 Sep. 2011 A | 137.482 | 0 | 0 | $0 |
| Pamela Pavco | · | 24 Sep. 2011 A | 44.940 | 0 | 0 | $0 |
| CYTRX CORP | · | 29 Des. 2010 S | 0 | 0 | 0 | $0 |
| Tod Woolf | · | 15 Jan. 2009 A | · | 0 | 0 | $0 |
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Kepemilikan ETF Dimiliki oleh 26 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.
| Dana | Bobot | Unit | Per tanggal | Sumber |
|---|---|---|---|---|
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,86% | 285.002 SH | 1 Okt. 2026 | Harian |
| BBC · ETFis Series Trust I | 0,86% | 39.695 NS | 31 Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,60% | 640.712 SH | 11 Sep. 2026 | Harian |
| LABU · Direxion Shares ETF Trust | 0,59% | 293.250 NS | 31 Juli 2026 | N-PORT |
| VFMO · VANGUARD WELLINGTON FUND | 0,23% | 316.525 SH | 19 Agu 2026 | Harian |
| ICOP · iShares Trust | 0,21% | 131.527 SH | 11 Sep. 2026 | Harian |
| IWO · iShares Trust | 0,17% | 1.775.566 SH | 11 Sep. 2026 | Harian |
| PWS · Pacer Funds Trust | 0,17% | 4.006 NS | 31 Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,16% | 202.339 SH | 19 Agu 2026 | Harian |
| IWM · iShares Trust | 0,08% | 4.838.243 SH | 11 Sep. 2026 | Harian |
| ISCG · iShares Trust | 0,08% | 57.697 SH | 11 Sep. 2026 | Harian |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,08% | 1.086.285 SH | 19 Agu 2026 | Harian |
| RSSL · Global X Funds | 0,06% | 90.355 NS | 31 Juli 2026 | N-PORT |
| ESML · iShares Trust | 0,05% | 105.699 SH | 11 Sep. 2026 | Harian |
| PICK · iShares, Inc. | 0,05% | 147.515 SH | 11 Sep. 2026 | Harian |
| VHT · VANGUARD WORLD FUND | 0,04% | 540.244 SH | 19 Agu 2026 | Harian |
| ISCF · iShares Trust | 0,04% | 30.200 SH | 11 Sep. 2026 | Harian |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 2.134.285 SH | 19 Agu 2026 | Harian |
| WSML · iShares Trust | 0,03% | 17.066 SH | 11 Sep. 2026 | Harian |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 85.332 NS | 31 Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 273.788 SH | 11 Sep. 2026 | Harian |
| IWV · iShares Trust | 0,00% | 44.399 SH | 11 Sep. 2026 | Harian |
| IXUS · iShares Trust | 0,00% | 98.316 SH | 11 Sep. 2026 | Harian |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 5.908.560 SH | 19 Agu 2026 | Harian |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 15.706 SH | 19 Agu 2026 | Harian |
| ISCB · iShares Trust | · | 8.283 SH | 11 Sep. 2026 | Harian |
SLS Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
Target Harga 12 Bulan
2 analis · 2026-10-02Target rata-rata $32.50 +176,8%
Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor
Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.
| Ticker | Kapitalisasi Pasar | P/E | Pendapatan YoY | Margin Bersih | ROE | Margin Kotor |
|---|---|---|---|---|---|---|
| SLS | $577M | -15.1 | · | · | -55.4% | · |
| BEAM | $2.82B | -34.2 | 120.0% | -57.2% | -7.0% | · |
| CLDX | $1.81B | -7.0 | -78.0% | -16748.0% | -43.8% | · |
| IRON | $3.01B | -13.2 | · | · | -31.3% | · |
| NRIX | $1.80B | -5.8 | 53.9% | -314.9% | -53.6% | · |
| IMNM | $2.43B | -8.8 | -23.2% | -3060.0% | -47.0% | · |
| VRDN | $3.17B | -7.7 | 23359.9% | -483.6% | -55.4% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| ADMA | $4.34B | 30.4 | 19.6% | 28.8% | 33.6% | 57.4% |
Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini
Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.